stockrowelectroCore, Inc.
ECOR Healthcare Medical Devices
electroCore, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 27.2% from fiscal 2024.
- Revenue
- +11.5%
- EPS
- +67.5%
- Free cash flow
- −69.1%
- Total debt
- +0.86%
Quarter to September 2026, against a year earlier
Follow ECOR
Alert me
electroCore, Inc. (ECOR) EV/Sales
As of 5 November 2026, electroCore, Inc. (ECOR) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from −5.2× (March 2020) to 452× (September 2018); the current reading is higher than 50% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | (76.24%) |
| FY2024 | 4.4× | 203.84% |
| FY2023 | 1.4× | 690.57% |
| FY2022 | 0.2× | 79.43% |
| FY2021 | 0.1× | (99.12%) |
| FY2020 | 11.5× | 11.71% |
| FY2019 | 10.3× | (91.37%) |
| FY2018 | 120× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.6× | 24.24% |
| Jun 2026 | 2.1× | 40.62% |
| Mar 2026 | 1.5× | 43.47% |
| Dec 2025 | 1.0× | (12.26%) |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NYXH Nyxoah SA compare | 0.1× |
| OM Outset Medical, Inc. compare | 0.3× |
| LNSR LENSAR, Inc. compare | 1.0× |
| ZOMDF Zomedica Corp. compare | 1.3× |
| ECOR electroCore, Inc. | 2.1× |
| HYPR Hyperfine, Inc. compare | 2.3× |
| LUCD Lucid Diagnostics Inc. compare | 11.3× |
| MBOT Microbot Medical Inc. compare | 15.0× |
| SERA Sera Prognostics, Inc. compare | 641× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)